✦ LIBER ✦

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis

✍ Scribed by Kostantinos Zarogoulidis; Eufimia Boutsikou; Pavlos Zarogoulidis; Ellada Eleftheriadou; Theodore Kontakiotis; Hellie Lithoxopoulou; George Tzanakakis; Ioannis Kanakis; Nikos K. Karamanos

Publisher: John Wiley and Sons
Year: 2009
Tongue: French
Weight: 213 KB
Volume: 125
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.24470

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Bone metastases occur in 20–40% of patients with lung cancer. Recent studies demonstrate a direct antiproliferative effect of 3rd generation bisphosphonates (BPs) on lung tumors, which may influence the survival. Therefore, we examined the clinical impact of zoledronic acid (ZOL; Zometa®), a 3rd generation BP, with a focus on the survival, time to progression and pain effect in lung cancer patients with bone metastases. Lung cancer patients (n = 144, Stage IV) with evidence of metastasis bone scan were included. Eighty‐seven of 144 experienced bone pain and received ZOL, 4 mg i.v. every 21 days (Group A), whereas the other 57 patients received no ZOL (Group B). All patients were treated with a combination chemotherapy consisted of docetaxel 100 mg/m^2^ and carboplatin AUC = 6. It was found that Group A had a statistically significant longer survival (p < 0.01) when compared to Group B. A statistically significant positive correlation was found between the number of cycles of therapy with ZOL and total patient survival (p < 0.01, Pearson correlation) and time to progression (p < 0.01). Pain effect of ZOL had no significant difference between the 2 groups of patients (p > 0.05). Urine N‐telopeptide of type I collagen (NTx) levels decreased in patients with NTx ≤ 29 nM BCE/mM creatinine at baseline after treatment with ZOL. The results of our study suggest that the addition of ZOL increases overall survival in lung cancer patients with bone metastases. The longer period of receiving ZOL, the better effect on survival and time to progression. © 2009 UICC

📜 SIMILAR VOLUMES

Thoracic radiation therapy improves the

Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis

✍ Hui Zhu; Zongmei Zhou; Yan Wang; Nan Bi; Qinfu Feng; Junling Li; Jima Lv; Dongfu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB 👁 1 views

## BACKGROUND: The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive-stage small cell lung cancer (ED-SCLC). METHODS: Between January 2003 and December 2006, the records of 119 patients who were diagnosed with ED-SCLC (a

The risk of renal impairment in hormone-

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

✍ William K. Oh; Kevin Proctor; Mari Nakabayashi; Carolyn Evan; Lauren K. Tormey; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Normalization of bone markers is associa

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

✍ Allan Lipton; Richard Cook; Fred Saad; Pierre Major; Patrick Garnero; Evangelos 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

## Abstract ## BACKGROUND. For patients with bone metastases, high N‐telopeptide of type I collagen (NTX) levels correlate with increased risks of skeletal‐related events and death. However, the relation between NTX decreases and clinical benefits is unclear. ## METHODS. Correlations between NTX

Effects of oral UFT combined with or wit

Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer

✍ Toru Hiraga; Akimi Ueda; Daisuke Tamura; Kenji Hata; Fumiyo Ikeda; Paul J. Willi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 238 KB 👁 1 views

Bone metastasis is one of the major causes of increased morbidity and eventual mortality in breast cancer patients. Therefore, intervention of bone metastases is one of the important targets in the management of breast cancer. In the present study, we examined the effects of the orally administrable

Impact of lymph-node metastasis site in

Impact of lymph-node metastasis site in patients with thoracic esophageal cancer: Does the lymph node metastasis site matter?

✍ Kang-Ning Wang; Qi-Rong Xu; Long-Qi Chen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB

The prognostic impact of cytokeratin-pos

The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer

✍ Wolfgang Lilleby; Jahn M. Nesland; Sophie D. Fosså; Goran Torlakovic; Håkon Waeh 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 145 KB 👁 1 views

## Abstract Our study evaluates the prognostic significance of the cytokeratin‐positive mononuclear cells (CK+ cells) in the bone marrow (BM) and peripheral blood (PB) as detected by immunocytochemistry in patients with locoregionally confined prostate cancer. BM and PB samples were obtained from 6